Zobrazeno 1 - 5
of 5
pro vyhledávání: '"celine Poussereau-Pomie"'
Autor:
Michael R. Paillasse, James Garner, Michael Fitzgerald, Lise Davenne, Pierre-Benoit Ancey, celine Poussereau-Pomie, Michael Esquerre, Gaelle Badet, Joel Tuyaret, Marie Mandron, Philippe Rochaix, Maha Ayyoub, Clara Maria Scarlata, Christine Ménétrier-Caux, Chrsitophe CAUX, Philippe Cassier, Jean-Pierre Delord, Carlos Gomez Roca, Pierre Fons
Publikováno v:
Cancer Research. 82:3203-3203
Introduction: EVT801 is a highly selective small molecule inhibitor of VEGFR3 and acts by inhibiting lymphangiogenesis and tumor angiogenesis in and around the tumor. It has shown compelling activity in a wide range of cancer models and is well-toler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad6e685d7e1bfe24767d84b1ebbaadae
https://doi.org/10.1158/1538-7445.am2022-3203
https://doi.org/10.1158/1538-7445.am2022-3203
Autor:
Stephanie Versluys, Pierre Fons, Michael R. Paillasse, Celia bergeaud, Federica Ferigo, Andrew Simon Bell, Richard Cox, Jérémy Besnard, Eric Cogo, Simone Culurgioni, Sean Robinson, Frederic Machet, Sabrina Pagliarusco, Emilie Pelissier, Craig Johnstone, Iva Hopkins-Navratilova, Jerome Menegotto, Emilie Mirey, Michael Esquerre, Joanna Lisztwan, Florie Bertrand, Virgile Visentin, Celine Poussereau-Pomie, Andrew Payne, Adrian Schreyer, Andrew L. Hopkins, Mark Whittaker
Publikováno v:
Cancer Research. 79:519-519
Evotec and Exscientia are collaborating to develop an innovative drug discovery platform for accelerating small molecule development in Immuno-Oncology. The primary focus is to target the immunosuppressive adenosine pathway. We have firstly sought to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01d93767d9b8f4fca64cf05cb71ac2ed
https://doi.org/10.1158/1538-7445.am2019-519
https://doi.org/10.1158/1538-7445.am2019-519
Autor:
Michael Esquerre, Florie Bertrand, Celia bergeaud, Andrew Simon Bell, Ghislaine Marchand, Simone Culurgioni, Michael R. Paillasse, Peter N. Ray, Emilie Pelissier, Craig Johnstone, Iva Hopkins-Navratilova, Leonardo-Silvestre Hernani, Jérémy Besnard, Sean Robinson, Mark Whittaker, Joanna Lisztwan, Stephanie Versluys, Andrew L. Hopkins, Andrew Payne, Pierre Fons, Adrian Schreyer, Celine Poussereau-Pomie, Richard S. Cox
Publikováno v:
Cancer Research. 79:507-507
Adenosine generated by CD73 is a key driver of immunosuppression in the hypoxic tumour microenvironment (TME) and particularly involved in angiogenic process and immunity. In immune-inflamed tumours, with CD8+ T-cell infiltrates, adenosine signalling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85b4f3ba878b339271551e8b3f442d29
https://doi.org/10.1158/1538-7445.am2019-507
https://doi.org/10.1158/1538-7445.am2019-507
Autor:
Françoise Bono, Pierre Fons, Donogh O'Brien, Florie Bertrand, Michael R. Paillasse, Anne Gomez-Brouchet, Janick Selves, Michael Esquerre, Antoine Alam, Mark Whittaker, Anne Pradines, Celine Poussereau-Pomie, Philippe Rochaix, Julien Mazieres, Joanna Lisztwan, Isabelle Rouquette, Jerome Meneyrol, Isabelle Blanc
Publikováno v:
Cancer Research. 78:2753-2753
Amongst resistance mechanisms of immune checkpoint therapies (ICTs), expansion and recruitment of immunosuppressive innate cells and in particular Myeloid Derived Suppressor Cells (MDSCs) can be a major cause of resistance to ICTs. Here we describe j
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edd8f4e28186dd1d142016a2722aa4d1
https://doi.org/10.1158/1538-7445.am2018-2753
https://doi.org/10.1158/1538-7445.am2018-2753
Autor:
Richard Cox, Adrian Schreyer, Celine Poussereau-Pomie, Andrew L. Hopkins, Stephanie Versluys, Michael Esquerre, Pierre Fons, Jérémy Besnard, Michael R. Paillasse, Andrew Simon Bell, Mark Whittaker, Florie Bertrand, Craig Johnstone, Joanna Lisztwan, Mark Swindells
Publikováno v:
Cancer Research. 78:3768-3768
Adenosine, generated by CD73 is a key driver of immunosuppression in the hypoxic tumour microenvironment (TME). In immune-inflamed tumours, with CD8+ T-cell infiltrates, adenosine signalling is a cause of resistance to immune checkpoint therapies (IC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::391376232655227ad997458acc2c5053
https://doi.org/10.1158/1538-7445.am2018-3768
https://doi.org/10.1158/1538-7445.am2018-3768